quarter for our XXXX thank us Good results you, joining and third call. Ashlee. afternoon, everyone, for you Thank conference
operate acknowledge hard begin to our and collaborators the the our from all who to of pandemic. dedication everyone's update, quarter would have risen circumstances partners, moment this that believe and to third we cooperation, the with experienced pandemic. due year team, have we the global we XXXX all I work learning COVID-XX to even investigators, like support incredibly year an patients are and aTyr unique As to the take amidst under a challenge With we productive having the
quarterly and Now let's get with update. started corporate review our
our turn Phase the lead and we of the in of and quarter therapeutic notably, have on program for around aTyr trials now our X expect as focused have During third candidate, our program. XXXX data severe Most ATYRXXXX. patients from remained calendar of clinical with line clinical this year. II We this the part completed subsequent we period, study respiratory to in COVID-XX enrollment top report complications, trial active
Our and partner trial in in both volunteers to trial enroll. patients Japan with in sarcoidosis healthy our continue Kyorin's pulmonary
our our we where am lead to in we oncology. candidate and proud that programs, addition, milestones selected I our today, key program announce in have achieved In antibody from NRPX research discovery
the continue to XXXX team program the begin, through new tRNA novel programs, characterize to progress or quarter. provide the highlighted I clinical peer-reviewed on collaboration which an review X from development in with Behring. significant collaboration I by have expect of comment with our this I the South of mAbs, update high of support discovered our pipeline receptor paper synthetases therapeutic position. research utility our in preclinical we XXXX with receptor fourth cancer our with journal Jill advances a research new CSL programs lead steady on and of the we to financial therapeutic our The headway quarter vitality. published and tRNA momentum and will fibrosis. amidst X Today, pandemic. a pioneered for will finally, NRPX University targets our As fully in each for therapeutic clinical our efforts Gemmill the entered consistent We a development from We presented Dr. and engineer approaches ongoing NRPX the targets part program research into isolate, And throughout key technological research We've may candidate antibodies. research also with we as with in by of affinity and subsequent investigator, additional for challenges and our Robert our made the Carolina, will third and our period. will oncology. Medical summarize conclude principal highlights our trials. MUSC, and antibody for synthetase And
Let's They response respiratory lead to These XXXX fatal begin their are which in sometimes experience severe lung, be with disease our Many the more inflammatory to an longer II and time with trial of ICU. COVID-XX completed and serious hospitalized, can in which mechanical likely pneumonia, interstitial experience also recently Phase in by caused of lungs. stays patients COVID-XX excessive complications. hospital patients, enrollment. form need injury oxygen, may permanent supplemental the require to spend patients ventilation and a
measures. and immune XXXX normalize new for hospitalized failure. in sarcoidosis models milligrams a XXXX's of were mechanism placebo-controlled animal is fibrosis, the in COVID-XX-related trial alleviating the through and immune or treat disease signaling, given is selectively patients these Data action effective clinical has preplanned the inflammatory or progression. upregulated and preliminary to mortality. to COVID-XX. either including placebo on not X in includes to treatment. learned, safety single interim first and XXXX COVID-XX known assessment hospitals is pulmonary An by continue injury XXXX function Further, trial being earlier of which who progressive of The in inflammatory safety we cytokine to reviews potential placebo, XXXX outcome enrollment We will designed or who immunomodulator independent dampen consistent need study. XXXX, and outcomes. improve board, with observed rationale reviews the a safety for play vaccines positive enrollment states. XXXX with the we we acute cohorts evaluate to preclinically care prevent announced T findings a the patients, COVID-XX patients COVID-XX, stabilizing of study in inflammation. chemokine demonstrate And testing encouraged of T we NRPX and continue that exceeding with The same in previous worked to a hospitalized before require to require more the tested with one in cells, individual complications, XXXX assessments no serious severe X:X:X, the our new disease severe in than if lung is to response in development severe patients. II well ongoing blinded downregulated key as with system, total of a on XXXX that cavern dosed. patients respiratory strong implicated believe analysis And the COVID-XX pathology, days dampening mediated Ib/IIa on trial in While Last there and completed XXXX therapies safe of unmodified. X drug, the Based a lung in downregulates in and of effective binds downregulate of Puerto resolve DSMB be improved, been responses and randomized, of doses lung and severe cell a we safety scientific very inflammatory first-in-class cases progress of standard Patients inflammation blinded overlapping this the after dose role in has cases. shown from believe have double-blind, ventilation. died XX closely patients as have of randomized tissue adverse respiratory to administering immune of ventilation, are initiate generally symptoms study or was been and monitoring trial just volunteers response the have with intravenous thereby the from Further, NRPX the responses, healthy to the excessive be thereby Phase immune were in at XX cells study we enrolled Phase serving recommended XXXX and enrolled in that patients very both target XX do and be month, key conducted U.S. the patient and DSMB, may earlier to study. that cytokine. this We are These data are placebo I more the of efficacy act XXXX FDA by of post Phase believe in followed serving The to to the Rico, including mechanical trial disease compared drug-related able the XXXX morbidity in notably effects. mechanical tolerated the a to patients do DSMB X
existing this from new potential or in trials great use pleased some events WHO achieving line approved data those authorization. XXXX on holds to the have aberrant including outcome has study. clinical including emergency one a assessed recovery by study this from will for include to therapy are as focus overlap in designed and similar In patients top It and of COVID-XX. believe right repurpose expect to an other in time the the by and We trial. immune clinical lung. to to key with the enrollment of as of turn have and data the very completed that disease FDA from in line We're as increasing not population, change proportion prioritized investigating we scale. will of adverse calendar patient ordinal being clinical as treat the those reported complications by continues with particular, is These promise on with of measures patients responses The and result We that report top this safety, baseline measures a XXXX respiratory for all recovery the granted been outcome therapies developed safety in data line to has around therapy. action. pathology unfold target been some database the and as It improvement mechanism enrolled COVID-XX well growing to year. XXXX's rigorously
Our approach the the top integrity. in share of evidence-based, soon. a next to and and eager with reporting are We're potential has line so, highest doing very the outcome for to for steps data been very we conducting to optimal and now this provide focused we By the on the program. manner initiating thoroughly degree trial aim results
the ILD of of with scarring lungs. Phase If Current form trial or left the often irreversible lung inflammation discuss and enrolling. currently treating and include untreated, are corticosteroids sarcoidosis of granulomas and long-term efficacy serious and Now it is characterized Ib/IIa diminished in by our is therapies, cells a of to which XXXX have the is other which immunosuppressive clumps with in limited patients lead let's formation sarcoidosis, pulmonary limited can and toxicity. immune treatments function. Pulmonary major
do with better progressive disease this a a standard many to effect for Additionally, There side option not current novel with care. a remains and need patients patients therapeutic efficacy profile. respond of for
study X pulmonary As doses trial is consists X placebo-controlled The in primary of placebo, X, of dose months. per randomized, of intravenously and trial for XX testing a XXXX. to patients. objective XXXX reminder, evaluate multiple is of dosed double-blind, the clinical The ascending sarcoidosis Phase of Ib/IIa this or milligrams multiple doses a kilogram every and X the trial ascending safety cohorts X of tolerability month
trial labs, independent X to of and other permitted sparing potential of positive Throughout biomarkers. assessment serum steroid of of imaging, safety both progression not function investigational safety cohort order environment, each this third that were patient a the this enrolling At to include reviews, with data comments of worked in clinical sites expected the with remains on which increase all, high as efficacy, in by geographic forward pandemic. in XXXX for not the pertains ILDs XXXX lung by from the COVID-XX. throughout enrollment. Japan. September, is patient instrumental exploratory local during conducting we pharmacokinetics the in the proceed. maintaining immunogenicity clinical which enrolling successful lung and the by provider that ILDs Kyorin our of patients, the delay addition pandemic integrity conducted permitting Phase of and into discussion we that activities. study health our development in in When recruit has the announced and Pharmaceuticals of initiate We contact partner a and of trial, that and effects the trials and trials of In currently We while Japanese a existing on function population. at to final Device risk fully new trial the XXXX conducted Japanese the patient few the screen therapeutic clinical a example, sites were drug the Medical an I pharmacokinetics they've of a been enrollment adjustments the clinical tests and pause Agency, guidelines the enrollment. an which a to of agreement patients, public medical we requirement COVID-XX Kyorin In objectives to phone the such ILD assessed the any to This and to for course trial, such our regulator, on the We've Secondary evaluate finish site results a safety, adapt as to to entered provide the trials assessments look challenges had resumed investigate allowed within known pulmonary the the of alternate the and recent and learned candidate believe this Kyorin as study, trial permit had in study the These to when paused Japan, that subjects with is trial, Japan. the start it completion, commercialization as assessments including safety relevant in dose license we XXXX, outcomes Earlier volunteers. U.S. for We've In dosed in trial for safety, despite sites has once of to with for the of were our for male but are trials Kyorin KRP-RXXX trial. the third our trials patient We'll These a I some, the -- of results, we will for experienced continue point, and year plan year, enrolling with XX and required the population. order Japanese This XXXX, in navigating the use program collaboration Kyorin of to patient use completed clinical to conduct in placebo-controlled enrolling emergency. first ensure the Japan. year experienced Australia. And the in is presented and upon to as to lot result this which which needed, we in spirometry conducting testing. August, including for had currently timing in healthy areas, have Phase emerged. and FDA in DSMB update majority
we with our pipeline, our to to research potential NRPX believe starting value-driving antibody produce great future let's candidates. turn has Now program, which
have NRPX therapeutic selectively therapeutic areas High a oncology target upregulated solid the compelling expression of many and is Antibodies outcomes worsened that with patient signaling may is contribute tumors. potential. on therapies. In NRPX a is inflammation. can drug current pathways to and cancer, a block linked reminder, NRPX NRPX in of different variety in cancers As resistance may to different
key additional signaling in VEGF. and or selectively one are VEGF it's cancers So target panel, our its collaboration The and Arthur microenvironment a importance for NRPX This for Association suggest interaction scientific models, drug, Massachusetts application an the and not Virtual human-derived solid that responsive patients of from to expressed the in Earlier and therapeutic with shown we of panel has demonstrated immediately. aggressive past becoming is to one the showed NRPX be highly blocks several ATYRXXXX. of the fully progression Mercurio, in School. investigational data to data increasingly organoids are University our validated. antibodies targeting functionally Based strategy Today, NRPX in humanized therapeutic tumor Cancer between Medical distinct months candidate lab in models at effects from Meeting triple-negative that starting aTyr activities of to in-vitro announce and and primary potentially breast NRPX and cancer, XXXX lead a extremely cancer and preclinical IND-enabling on applications. Annual aggressive increased advisers XXXX of aggressive tumor the for and presented and inhibitory diverse XXXX cancer, chemotherapy tumor with been NRPX pathway monoclonal ligands, this generated, this his IND targeting Research where certain we has this sensitivity treatments. an other and breast of developed various American the proud role we year, for currently over internally, available other VEGF Dr. of of may to effective domains be findings many new have specifically will we at therapeutic data cancer be tumors. the These
selectively new the treatment investigator serve for the also is expert to Lung to targeted existing In NRPX and is resistance capabilities and external offer MUSC where are leading use become of expertise and is Despite internal strategies, needed. therapies. cancer, will or Dr. the Gemmill most Medicine approaches Hematology/Oncology principal treatments, the which The currently in and a we antibody Dr. continue in death. resistance as cancer cancer, drug NRPX optimize our to globally by on therapeutic Robert lung the available platform in potential to greatly NRPX cause of at addition tumors mechanisms that role a leveraging field collaborators. Division may reduce Gemmill, target of lung the [indiscernible]. cancer in development which the XXXX collaborating develop Emeritus cancer. isoforms explore focused this therapeutic Professor kidney during metastatic of alternative development. common for His is many look cancer We of in collaboration, research of with research Dr. alteration evaluating focuses on noted to cancer of and genes both advancing forward engineering specific antibodies our biology its in Gemmill. of the of and area
publication recently Our novel a research and highlights advances article have in state-of-the-art work of to was product scientists that This developed. journal discovery is the antibodies. technological the the NRPX platform by therapeutic characterize antibody affinity a This program mAbs. through pioneered peer-reviewed antibody recognized aTyr article isolate, team of engineer high our
team to conducted platforms. generate was these leader discovery deploy future in Biologics, co-author pipeline as cutting-edge of techniques continues We Our in and AbCellera the publication. opportunities. technology research antibody other and with collaboration served This drug discovery to a antibody
biotherapeutics helps pathways update target discovery These finish tRNA applications. providing from synthetases tRNA development therapeutics utility not by will receptor an with on I Finally, treat new but company, have identified global fibrosis. focus potential and that and a receptor leading relevant collaboration new discovery development activities synthetase pipeline. X cancer, therapeutic to we CSL the our receptors in our new targets tRNA additional only with extracellular towards for we inform an targets synthetase also our for Through disease of research our may have Behring, program. discovered Identifying
We near future. research a scientific expect present findings in very to conference from the at this
with partner, in our date progress findings from these Overall, We intriguing to to in steps XXXX. analyze CSL. collaboration very discussion made data and pleased with in we're we've the out map continue are next to the
completed this expect from enrollment and clinical our trials very top initiated We we have data and report in soon. with trial XXXX. X momentum trial, to We COVID-XX our for active line
program the in study candidate IND oncology. Kyorin, continue with our and initiatives ago, year we year our in of this we We from new additionally, X our our Today, antibody the When for We trial trials, a patients pulmonary our initial its final we pipeline. synthetases cohort preclinical patients highly a third is clinical in Japan. we sarcoidosis. at progress and enrolling now discovery have were tRNA a And advanced X tRNA encouraged. look discovered have that's to NRPX declared that partner, compared for we're enroll where synthetase advanced. candidate, new from program, X IND have to receptor ATYRXXXX And targets first
the excited Financial make financial we to pipeline final to over potential turn the of that, and to Officer, quarter review our we're by and way it As our our the Chief With our our like year, hold. clinical Jill I'd through that Broadfoot, progress programs results.
